# US 2021/0275523 A1 · Treatment for obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275523 A1
- Document ID: US20210275523A1
- Status: Published application
- Kind: A1
- Application number: 17/276,821
- Filed: 2019-09-18
- Published: 2021-09-09
- Earliest claimed: 2018-09-18
- Assignees: 1Globe Biomedical Co., Ltd.; 1Globe Health Institute LLC
- Applicants: 1Globe Biomedical Co., Ltd.; 1Globe Health Institute LLC
- Inventors: Chiang J. LI; Zoltan DERDAK; Darko STEVANOVIC; Jifeng LIU
- Web page: https://patentgrep.com/patent/US20210275523A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D 403/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention provides novel methods of treating or preventing obesity or overweight and closely associated comorbidities therewith in a mammalian subject including human.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and the metabolic syndrome in a mammal, comprising administering to a mammalian subject in need thereof:
(a) a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula I:
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof that is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes and the metabolic syndrome in a mammal, and
wherein the symbols have the following meanings and are, for each occurrence, independently selected:
R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, ORa, SRa, S(═O)2Re, S(═O)2ORe, C(═O)ORd, C(═O)Ra, or C(═O)NRbRc;
R2 is heterocycle or substituted heterocycle, aryl or substituted aryl;
R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl;
R4, R7, and R8 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, ORa, SRa, S(═O)Re, S(═O)2Re, P(═O)2Re, S(═O)2ORe, P(═O)2ORe, NRbRc, NRbS(═O)2Re, NRbP(═O)2Re, S(═O)2NRbRc, P(═O)2NRbRc, C(═O)ORe, C(═O)Ra, C(═O)NRbRc, OC(═O)Ra, OC(═O)NRbRc, NRbC(═O)ORe, NRdC(═O)NRbRc, NRdS(═O)2NRbRc, NRdP(═O)2NRbRc, NRbC(═O)Ra, or NRbP(═O)2Re;
R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino;
R6 is hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or ORa;
Ra is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl;
Rb, Rc and Rd are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or said Rb and Rc together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle;
Re is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; and
(b) a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 3 (depends on 2)

The method of claim 2, wherein the compound of Formula I is further a compound of Formula II:
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof that is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes and the metabolic syndrome in a mammal, and
wherein the symbols have the following meanings and are, for each occurrence, independently selected:
Het is a 5- or 6-membered aromatic ring containing at least one heteroatom selected from N, O and S;
R3 and R10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl;
R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or ORa; and
R14 and R15 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or said R14 and R15 together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle.

### Claim 4 (depends on 3)

The method of claim 3, wherein the compound of Formula II is further a compound of Formula III:
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof that is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes and the metabolic syndrome in a mammal, and
wherein the symbols have the following meanings and are, for each occurrence, independently selected:
R11 is hydrogen or C1-4 alkyl;
R12 and R13 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or said R12 and R13 together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle; and
n is an integer selected from 2, 3, 4, 5 and 6.

### Claim 5 (depends on 3)

The method of claim 3, wherein the compound of Formula II is further a compound of Formula IV:
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof that is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes and the metabolic syndrome in a mammal.

### Claim 6 (depends on 4)

The method of claim 4, wherein the compound of Formula III is further a compound of Formula V:
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof that is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes and the metabolic syndrome in a mammal.

### Claim at position 7

7-11. (canceled)

### Claim 12 (depends on 2)

The method of claim 2, further comprising administering an additional agent selected from the group consisting of: an insulin sensitizing medication, a diabetes medication, a therapeutic for the metabolic syndromes, and a weight-loss medication.

### Claim at position 9

13-16. (canceled)

### Claim 17 (depends on 2)

The method of claim 2, wherein the mammal is a human.

### Claim 18 (depends on 2)

The method of claim 2, wherein the compound of Formula I is selected from the group consisting of:

### Claim 19 (depends on 2)

The method of claim 2, wherein the compound of Formula I comprises at least one deuterium, and is selected from the group consisting of:
and an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof.

### Claim 20

A method for reducing or ameliorating morbidity or mortality known to be associated with obesity, overweight, type II diabetes and the metabolic syndrome in a mammal, comprising administering to a mammalian subject in need thereof:
(a) a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula I:
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof that is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes and the metabolic syndrome in a mammal, and
wherein the symbols have the following meanings and are, for each occurrence, independently selected:
R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, ORa, SRa, S(═O)2Re, S(═O)2ORe, C(═O)ORd, C(═O)Ra, or C(═O)NRbRc;
R2 is heterocycle or substituted heterocycle, aryl or substituted aryl;
R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl;
R4, R7, and R8 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, ORa, SRa, S(═O)Re, S(═O)2Re, P(═O)2Re, S(═O)2ORe, P(═O)2ORe, NRbRc, NRbS(═O)2Re, NRbP(═O)2Re, S(═O)2NRbRc, P(═O)2NRbRc, C(═O)ORe, C(═O)Ra, C(═O)NRbRc, OC(═O)Ra, OC(═O)NRbRc, NRbC(═O)ORe, NRdC(═O)NRbRc, NRdS(═O)2NRbRc, NRdP(═O)2NRbRc, NRbC(═O)Ra, or NRbP(═O)2Re;
R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino;
R6 is hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or ORa;
Ra is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl;
Rb, Rc and Rd are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or said Rb and Rc together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle;
Re is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; and
(b) a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 21 (depends on 20)

The method of claim 20, wherein the compound of Formula I is further selected from the group consisting of:
and an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof.

### Claim 22 (depends on 20)

The method of claim 20, wherein the compound of Formula I comprises at least one deuterium, and is selected from the group consisting of:
and an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof.

### Claim 23 (depends on 20)

The method of claim 20, wherein the compound of Formula I is further a compound of Formula IF
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof that is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes and the metabolic syndrome in a mammal, and
wherein the symbols have the following meanings and are, for each occurrence, independently selected:
Het is a 5- or 6-membered aromatic ring containing at least one heteroatom selected from N, O and S;
R3 and R10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl;
R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or ORa; and
R14 and R15 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or said R14 and R15 together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle.

### Claim 24 (depends on 23)

The method of claim 23, wherein the compound of Formula II is further a compound of Formula III:
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof that is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes and the metabolic syndrome in a mammal, and
wherein the symbols have the following meanings and are, for each occurrence, independently selected:
R11 is hydrogen or C1-4 alkyl;
R12 and R13 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or said R12 and R13 together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle; and
n is an integer selected from 2, 3, 4, 5 and 6.

### Claim 25 (depends on 23)

The method of claim 23, wherein the compound of Formula II is further a compound of Formula IV:
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof that is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes and the metabolic syndrome in a mammal.

### Claim 26 (depends on 24)

The method of claim 24, wherein the compound of Formula III is further a compound of Formula V:
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof that is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes and the metabolic syndrome in a mammal.

### Claim 27 (depends on 20)

The method of claim 20, wherein the mammal is a human.

### Claim 28 (depends on 20)

The method of claim 20, further comprising administering an additional agent selected from the group consisting of: an insulin sensitizing medication, a diabetes medication, a therapeutic for the metabolic syndromes, and a weight-loss medication.

### Claim 29 (depends on 20)

The method of claim 20, wherein morbidity or mortality known to be associated with obesity, overweight, type II diabetes and the metabolic syndrome is selected from the group consisting of: excessive weight, excessive fat, a BMI≥25 kg/m2, insulin resistance, frequent urination, increased thirst, increased hunger, elevated blood pressure, elevated fasting plasma glucose, high serum triglycertides, low high-density lipoprotein (HDL) levels, and elevated waist circumference.

### Claim 30 (depends on 29)

The method of claim 29, wherein the morbidity or mortality is a BMI≥30 kg/m2.
